These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19931447)

  • 1. Visualizing cancer and immune cell function with metabolic positron emission tomography.
    Laing RE; Nair-Gill E; Witte ON; Radu CG
    Curr Opin Genet Dev; 2010 Feb; 20(1):100-5. PubMed ID: 19931447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET probes for distinct metabolic pathways have different cell specificities during immune responses in mice.
    Nair-Gill E; Wiltzius SM; Wei XX; Cheng D; Riedinger M; Radu CG; Witte ON
    J Clin Invest; 2010 Jun; 120(6):2005-15. PubMed ID: 20484820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging of Tumor Metabolism Using Positron Emission Tomography (PET).
    Apostolova I; Wedel F; Brenner W
    Recent Results Cancer Res; 2016; 207():177-205. PubMed ID: 27557539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET/CT imaging in cancer: current applications and future directions.
    Farwell MD; Pryma DA; Mankoff DA
    Cancer; 2014 Nov; 120(22):3433-45. PubMed ID: 24947987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging.
    Rajendran JG; Mankoff DA; O'Sullivan F; Peterson LM; Schwartz DL; Conrad EU; Spence AM; Muzi M; Farwell DG; Krohn KA
    Clin Cancer Res; 2004 Apr; 10(7):2245-52. PubMed ID: 15073099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine.
    Buck AK; Herrmann K; Shen C; Dechow T; Schwaiger M; Wester HJ
    Methods; 2009 Jun; 48(2):205-15. PubMed ID: 19318128
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Mitchell KG; Amini B; Wang Y; Carter BW; Godoy MCB; Parra ER; Behrens C; Villalobos P; Reuben A; Lee JJ; Weissferdt A; Moran CA; Fujimoto J; Sepesi B; Walsh GL; Vaporciyan AA; Hofstetter WL; William WN; Gibbons DL; Wang J; Hwu P; Swisher SG; Piwnica-Worms D; Kadara H; Wistuba II; Heymach JV; Peng W; Cascone T
    Cancer Immunol Immunother; 2020 Aug; 69(8):1519-1534. PubMed ID: 32300858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron Emission Tomography Computed Tomography: A Guide for the General Radiologist.
    Beadsmoore C; Newman D; MacIver D; Pawaroo D
    Can Assoc Radiol J; 2015 Nov; 66(4):332-47. PubMed ID: 26277234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioneering and fundamental achievements on the development of positron emission tomography (PET) in oncology.
    Fukuda H; Kubota K; Matsuzawa T
    Tohoku J Exp Med; 2013 Jul; 230(3):155-69. PubMed ID: 23883588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET imaging for assessing tumor response to therapy.
    Mankoff DA; Katz SI
    J Surg Oncol; 2018 Aug; 118(2):362-373. PubMed ID: 29938396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2'-deoxycytidine analog.
    Radu CG; Shu CJ; Nair-Gill E; Shelly SM; Barrio JR; Satyamurthy N; Phelps ME; Witte ON
    Nat Med; 2008 Jul; 14(7):783-8. PubMed ID: 18542051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Utility of [
    Beinat C; Haywood T; Chen YS; Patel CB; Alam IS; Murty S; Gambhir SS
    Mol Imaging Biol; 2018 Dec; 20(6):1015-1024. PubMed ID: 29736561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated whole-body PET/MR hybrid imaging: clinical experience.
    Quick HH; von Gall C; Zeilinger M; Wiesmüller M; Braun H; Ziegler S; Kuwert T; Uder M; Dörfler A; Kalender WA; Lell M
    Invest Radiol; 2013 May; 48(5):280-9. PubMed ID: 23442775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of clinical practice utility of positron emission tomography with 18F-fluorodeoxyglucose in assessing tumour response to therapy.
    d'Amico A
    Radiol Med; 2015 Apr; 120(4):345-51. PubMed ID: 25155349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of dedicated breast positron emission tomography and whole-body positron emission tomography/computed tomography images: a common phantom study.
    Satoh Y; Motosugi U; Imai M; Onishi H
    Ann Nucl Med; 2020 Feb; 34(2):119-127. PubMed ID: 31768819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer.
    Kim CY; Jeong SY; Chong GO; Son SH; Jung JH; Kim DH; Lee SW; Ahn BC; Lee J
    Gynecol Oncol; 2015 Mar; 136(3):498-504. PubMed ID: 25557270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Positron emission tomography: basic principle and radionuclides/probes for metabolic/functional analysis].
    Saga T; Yoshikawa K; Ishizu K
    Rinsho Byori; 2007 Jul; 55(7):630-8. PubMed ID: 17718059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive imaging of adaptive immunity using positron emission tomography.
    Nair-Gill ED; Shu CJ; Radu CG; Witte ON
    Immunol Rev; 2008 Feb; 221():214-28. PubMed ID: 18275485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine.
    Wells P; West C; Jones T; Harris A; Price P
    Biochim Biophys Acta; 2004 Dec; 1705(2):91-102. PubMed ID: 15588764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical molecular imaging with positron emission tomography.
    Saleem A; Charnley N; Price P
    Eur J Cancer; 2006 Aug; 42(12):1720-7. PubMed ID: 16797972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.